- Supporting pharmaceutical, medical device, wellness, and research organizations in obtaining standardized sleep data
- Expanding the use of SOMNUM scoring technology to provide clinical analysis services tailored to each customer’s research objectives
- AI Technologies Supporting Global Clinical Trials in Drug Development
BOSTON, Oct. 1, 2026 /PRNewswire/ — More pharmaceutical companies and research organizations are turning to HoneyNaps, an AI-based sleep health technology company, for objective analysis and validation of sleep data. Demand spans clinical trials of sleep medications, evaluations of wellness sleep devices and home-care products, and studies involving positive airway pressure (PAP) therapy and cardiovascular disease. In response, HoneyNaps is broadening the scope of its clinical analysis services.
SOMNUM Clinical Trials
HoneyNaps has completed registration as a clinical research organization (CRO) with the Korea National Enterprise for Clinical Trials (KoNECT). It combines AI-powered sleep analysis technology with experience supporting clinical trials involving more than 10,000 participants and the capabilities to operate multicenter, multidisciplinary studies. Its clinical sleep data analysis services quantify key physiological measures obtained through polysomnography (PSG), including sleep stages, respiratory events, and arousals, and support the analysis of clinical endpoints aligned with each study’s objectives.
Although research objectives vary across sectors, pharmaceutical companies, device developers, and research organizations share a need for objective, consistent sleep data. Evaluating treatment response or device performance requires sleep metrics to be analyzed against consistent criteria while minimizing variability between institutions and scorers. The need to establish reliable and reproducible data is driving growing interest in HoneyNaps’ sleep analysis technology.
As demand for sleep data analysis and validation grows across sectors, HoneyNaps is extending its business beyond sleep scoring with its SOMNUM platform into clinical analysis services for the pharmaceutical, wellness, and medical device industries. Data quantifying sleep architecture and continuity, respiratory patterns, and oxygen saturation changes may also serve as foundational evidence for future digital biomarker development.
Taekyoung (Sean) Ha, PhD, President of HoneyNaps USA, said, “Pharmaceutical companies, device developers, and research organizations pursue different research objectives, but they share a need for objective and consistent sleep data. As more customers across these sectors turn to HoneyNaps to obtain such data, we are expanding both the applications of our existing scoring technology and the business areas that contribute to revenue.”
He added, “We will continue to support the generation of clinical evidence through endpoints suited to each study and standardized analysis criteria, while diversifying our revenue base.”
For further information, please contact:
HoneyNaps USA, Inc.
Christine Kwon / Managing Director
Email: [email protected]
Address: 14th Floor, One Broadway, Cambridge, MA 02142, USA
Website: www.honeynaps.com